A single, long-lasting jab that offers a “protective bubble” to premature babies from a common virus is set to be rolled out on the NHS in England this autumn. Experts say the drug will give thousands ...

EDP-323 Phase 2a Challenge Study Topline Results This Phase 2a study was a randomized, double-blind, placebo-controlled, human challenge study of 142 healthy adult participants inoculated with RSV.

EDP-938 is a nonfusion replication inhibitor of RSV that acts by modulating the viral nucleoprotein (N protein). 9,10 Findings from in vitro time-of-addition studies suggest that EDP-938 would be ...